3Agro KE, Bradley CA, Mittmann N, et al. Sensitivity analysis in health economic and pharmacoeconomic studies. Appraisal of the literature [J]. Pharmacoeconomies, 1997, 11(1): 75-88.
4Rubio M,Lizán L,Badia X,Escartín-Siquier A E,López-Trigo J,Rufo-Campos M,Echarri E.(Cost-minimisation analysis of the pharmacological treatment of epilepsy in Spain)Revista de Neurologia . 2006
5Arroyo S,Fossas P,Nieto-Barrera M,Salas-Puig X,Sánchez-Alvarez J C,Serratosa J M,Soler-Singla L,Heaney D C,Sander J W,Shorvon S.(Analysis of cost minimization of monotherapy antiepileptic treatment in patients with recent diagnosed epilepsy : the situation in Spain)Revista de Neurologia . 2000
6Hong Zhen,Qu Bo,Wu Xin-Tong,Yang Tian-Hua,Zhang Qin,Zhou Dong.Economic burden of epilepsy in a developing country: a retrospective cost analysis in China. Epilepsia . 2009
7Yoon Dokyoung,Frick Kevin D,Carr Deborah A,Austin Joan K.Economic impact of epilepsy in the United States. Epilepsia . 2009
8ILAE Commission Report.The epidemiology of the epilepsies: future directions. Epilepsia . 1997
9M Connock,E Frew,B-W Evans, et al.The clinical effectiveness and cost-effectiveness of newer drugs for children with epilepsy. A systematic review. Health Technology . 2006
10Henke GJ,Williamson AA,Mazonson PD.Cost- effectiveness of three common antiepileptic medication. Epilepsia . 1994
